The batch manufacturing record in the Pharmaceutical Industry
Last updated: 27. March 2026
Companies in the pharmaceutical industry are legally required to maintain a seamless batch manufacturing record for every production unit. This documentation step records the entire production process and ensures that all work steps have been carried out in accordance with GMP (Good Manufacturing Practice) guidelines. The goal is complete traceability and the assurance of data integrity throughout the entire life cycle of the batch: from the substances used to every process step, down to the individuals responsible for execution and control, every detail must be documented.
These batch logs are internationally known as the Batch Manufacturing Record (BMR) or Batch Production Record (BPR). They are mandatory worldwide – while the EU GMP Guidelines are authoritative in Europe, the USA follows the FDA's CFR regulations. However, both demand an identical depth of documentation to bring medicinal products to market with consistent quality.
The Difference from an Electronic Batch Record (EBR)
While traditional batch logging was done in paper form for years, the electronic version – the Electronic Batch Record (EBR) – is gradually replacing the analog process. Paper-based entries are prone to manual transcription errors and often violate the ALCOA+ principles (Attributable, Legible, Contemporaneous, Original, Accurate), as timestamps or legibility after corrections are difficult to validate.
EBR systems, on the other hand, automate data collection in real-time and ensure compliance through system-supported checks. In short: the electronic manufacturing record is the result of digitalization and the efficient successor to the paper report.
What does the Batch Report include?
The batch manufacturing record must map every process step without gaps. In the world of regulatory authorities, the strict principle applies: "What is not documented has not happened." Therefore, in addition to the batch number and production date, the record includes all materials used as well as every sub-step of manufacturing.
After completion of production and all in-process controls, a systematic review takes place. The final certification and release of the batch for the market in the EU may only be carried out by a Qualified Person (QP) in accordance with Section 14 of the German Medicines Act (AMG). This person formally confirms that the batch was manufactured in accordance with GMP rules and the marketing authorization. Electronic signatures in EBR systems provide additional legal certainty here.
The record is based directly on the Master Batch Record (MBR), which serves as the approved template containing all binding target parameters. The actual record is technically a controlled copy of the MBR, which is filled with actual values during manufacturing.
Regulatory Requirements
Quality assurance monitors the reporting for each batch. A release only occurs if the actual values lie within the defined tolerance ranges. In the event of deviations, a root cause analysis is mandatory before a decision is made regarding the use of the batch. Strict EU GMP standards apply, as do FDA regulations for exports to the USA, particularly regarding data integrity (21 CFR Part 11).
Benefits of Logging
Today's documentation requirement is rooted in the 1960s: the 1962 Kefauver-Harris Amendment created the legal basis for GMP. Today, cGMP (Current GMP) demands continuous improvement. The benefits are:
- Minimizing the error rate in manufacturing.
- Guaranteeing consistent quality standards for patient protection.
- Efficiency through "Review by Exception": digital systems flag only deviations for manual review, which drastically shortens release times.
Challenges and Trends
The advantage of digitalization is particularly evident in highly automated systems such as Rommelag's Blow-Fill-Seal (BFS) systems: since forming, filling, and sealing take place in an integrated process, all critical parameters can be recorded digitally without media disruption and stored in a tamper-proof manner according to ALCOA+ principles.
In the future, technologies such as AI and blockchain will continue to shape batch manufacturing records – whether through the automated detection of process deviations or through forge-proof transparency throughout the entire supply chain.